Galmed Pharma: First Set Of Oncology Studies Show Aramchol Enhances Liver / Colorectal Cancer-approved Therapeutic Regorafenib Effects In Liver And Colon Cancers In-vitro And In-vivo Models

Author: Benzinga Newsdesk | May 06, 2025 07:39am

• Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models.
• The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.
• A Phase 1b Study of the addition of Aramchol to Regorafenib in patients with advanced GI cancers is planned to be initiated at VCU's Massey Cancer Center in Q4 2025.
• Leveraging on its long-standing experience in liver and metabolic diseases, Galmed plans to advance the novel combination oncology program in parallel to the recently announced Semaglutide GLP-1 development.

TEL AVIV, Israel, May 6, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has shown that Aramchol enhances the liver / colorectal cancer-approved therapeutic Regorafenib effects in liver and colon cancers in-vitro and in-vivo models.

Posted In: GLMD